Supplementary Table S1. Comparison of WHOQOL-BREF scores between patients after delabeling (POST) and before delabeling (PRE) and general population

| **WHOQOL-BREF domain** | **Delabelled group (mean ± SD)** | **Non-Delabelled group (mean ± SD)** | **U** | **p** | **r** | **POST (min - max)** | **PRE (min - max)** | **General population (mean ± SD)** † |
|---|---|---|---|---|---|---|---|---|
| Domain 1: Physical | 14.93 ± 3.05 | 14.58 ± 3.14 | 1128 | 0.61 | 0.05 | 9.14-19.43 | 6.29-20 | 16.2 ± 2.9 |
| Domain 2: Psychological | 17.02 ± 2.49 | 16.84 ± 2.63 | 1166 | 0.809 | 0.02 | 9.33-20 | 7.33-20 | 15.0 ± 2.8 |
| Domain 3: Social relationships | 17.25 ± 2.13 | 17.06 ± 2.57 | 1174.5 | 0.857 | 0.02 | 13.33-20 | 8-20 | 14.3 ± 3.2 |
| Domain 4: Environment | **17.15 ± 1.88** | **16.5 ± 1.82** | 893 | **0.029*** | 0.22 | 13-20 | 11-20 | 13.5 ± 2.6 |

Data are presented as mean ± standard deviation (SD) and range (min–max).

U: Mann-Whitney U test.

r: Effect size.

* $p < 0.05$

Abbreviations: WHOQOL-BREF, World Health Organization Quality of Life – BREF.
† Reference mean values derived from the international WHOQOL-BREF field trial (Skevington et al., 2004), based on a multinational general population sample.

Supplementary Table S2. Questions included in the author's questionnaires.

| **Delabelled group** | **Non-delabelled group** |
|---|---|
| The diagnostic procedures performed to exclude allergy (skin testing, sIgE provocation tests, interview with a physician); | The diagnostic procedures performed to diagnose allergy (skin testing, sIgE provocation tests, interview with a physician); |
| Patients' perceptions of the credibility of the delabeling process†; | Patients' perceptions of the credibility of the diagnostic process†; |
| Confidence in the safety of re-exposure to beta-lactam antibiotics†; | Confidence in the safety of beta-lactam antibiotic use†; |
| Clinical characteristics of previous reactions, including skin, respiratory, digestive, cardiovascular, and systemic symptoms; | Clinical characteristics of previous reactions, including skin, respiratory, digestive, cardiovascular, and systemic symptoms; |
| Antibiotic use between the initial diagnosis and the delabeling; | Alternative antibiotics used since the diagnosis. |
| Re-use of beta-lactam antibiotics following delabeling and adherence to the prescribed regimen; | Whether beta-lactam antibiotics had been prescribed since the initial labeling; |
| Occurrence of any recurrent symptoms after re-exposure, including skin, respiratory, cardiovascular, and other symptoms; | N/A |
| Patients' perceived confidence in taking a beta-lactam antibiotic when prescribed by an allergist compared with another physician.[1] | Patients' perceived confidence in taking a beta-lactam antibiotic when prescribed by an allergist compared with another physician.[1] |

†On a 1-10 scale.

[1] Answers to this question were omitted in the main manuscript, as the analysis of the results indicated that patients could have misunderstood the question due to the complexity of the Polish language.